최일규
Choi, Il-Kyu학력
- 2006 ~ 2012연세대학교 박사
- 2004 ~ 2006연세대학교 석사
- 1998 ~ 2004한국외국어대학교 학사
경력
- 2020 ~ 2021Dana-Farber Cancer Institute/Harvard Medical School / Instructor
- 2013 ~ 2019Dana-Farber Cancer Institute/Harvard Medical School / Postdoctoral Fellow
- 2012 ~ 2013Hanyang University / Postdoctoral Fellow
수상실적
- 2020 The 2019 Barr Fellow of Claudia Adams Barr Program / Dana-Farber Cancer Institute/Harvard Medical School
- 2015 Best Poster Award / Dana-Farber Cancer Institute/Harvard Medical School
- 2011 KSGCT Poster Prize / 한국유전자세포치료학회
- 2009 Poster Award for Excellence / 연세대학교
- 2008 Poster Award for Excellence / Korean Society for Biomedical Laboratory Sciences
연구실 소개
- Lab of T-cell Biology and Immunotherapy
-
Our laboratory aims to understand the fundamental biology of T cells in health and disease, and translate the discoveries into novel immunotherapeutic approaches for intractable diseases. With our own unique model systems, we currently focus on the following research projects which lie at the intersection of immunology, virology and cancer treatment. This research program, if successful, will place our lab in a unique position to open new avenues of research in the human virobiota and CD4 CTL biology, and lead to the development of innovative cancer immunotherapies.
Research Interests
Related Keyword
- "NKG2D-mediated cytotoxicity of CD4 cytotoxic T cells in multiple myeloma", Blood, v.146, no.4, pp.456 - 470
- "Recent advances in single-cell metabolomics using mass spectrometry: emerging challenges and future perspectives", Applied Spectroscopy Reviews, v.60, no.9-10, pp.832 - 868
- "IL2-mediated modulation of small extracellular vesicles secretion and PD-L1 expression: a novel perspective for neutralizing immune suppression within cancer cells", Noh, Soojeong. (2024-12). IL2-mediated modulation of small extracellular vesicles secretion and PD-L1 expression: a novel perspective for neutralizing immune suppression within cancer cells. Cancer Communications, 44(12), 1422–1426. doi: 10.1002/cac2.12623
- "CD4+ cytotoxic T cells: an emerging effector arm of anti-tumor immunity", Jeong, Seongmin. (2023-02). CD4+ cytotoxic T cells: an emerging effector arm of anti-tumor immunity. BMB Reports, 56(3), 140–144. doi: 10.5483/BMBRep.2023-0014
- "Does delayed EBV infection contribute to rising childhood cancers?", Zhang, Baochun. (2022-12). Does delayed EBV infection contribute to rising childhood cancers? Trends in Immunology, 43(12), 956–958. doi: 10.1016/j.it.2022.09.009
- "CD4 Cytotoxic T Cells Promote Antitumor Immunity in Multiple Myeloma", Kim, Sojeong. (2024-12-08). CD4 Cytotoxic T Cells Promote Antitumor Immunity in Multiple Myeloma. 66th Annual Meeting of the American Society of Hematology (ASH), 668–669. doi: 10.1182/blood-2024-199396
- "Cd70 Deficiency Impairs CD4+and CD8+T-Cell Immune Surveillance in Bcl6-Driven Diffuse Large B-Cell Lymphomas", Mandato, Elisa. (2023-11-02). Cd70 Deficiency Impairs CD4+and CD8+T-Cell Immune Surveillance in Bcl6-Driven Diffuse Large B-Cell Lymphomas. 65th Annual Meeting of the American-Society-of-Hematology (ASH), 1624–1625. doi: 10.1182/blood-2023-186297
연구분야
미래유망 신기술(6T)
국가과학기술표준분류